Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Silverback Therapeutics, Inc.

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
From Silverback Therapeutics, Inc.
Via GlobeNewswire
Tickers SBTX
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting 2021
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics Presents SBT6050-201 Trial in Progress Poster at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics to Present Data from its Phase 1/1b Clinical Trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo® (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics to Participate in the Raymond James Human Health Innovation Conference
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics Reports First Quarter 2021 Financial Results
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference
From Silverback Therapeutics, Inc.
Via Business Wire
Tickers SBTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.